Talaris Therapeutics, Inc.

NasdaqGM:TALS Stock Report

Market Cap: US$553.2m

Talaris Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mary Fenton

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage20.6%
CEO tenure2.6yrs
CEO ownership0.07%
Management average tenureno data
Board average tenure4.9yrs

Recent management updates

Recent updates

Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

May 24
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

Feb 14
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Oct 21
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris drops 24% after patient death in late-stage trial for lead asset

Oct 20

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Aug 29

Talaris Therapeutics GAAP EPS of -$0.44

Aug 15

We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Jul 06
We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Jun 30

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Mar 23
Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Talaris Therapeutics EPS beats by $0.49

Jun 14

CEO Compensation Analysis

How has Mary Fenton's remuneration changed compared to Talaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$75m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$2mUS$455k

-US$74m

Sep 30 2022n/an/a

-US$70m

Jun 30 2022n/an/a

-US$64m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$2mUS$340k

-US$48m

Compensation vs Market: Mary's total compensation ($USD2.21M) is about average for companies of similar size in the US market ($USD2.23M).

Compensation vs Earnings: Mary's compensation has been consistent with company performance over the past year.


CEO

Mary Fenton (59 yo)

2.6yrs

Tenure

US$2,209,223

Compensation

Ms. Mary Kay Fenton has been Chief Financial Officer at Talaris Therapeutics, Inc. since March 2021 and serves as its Treasurer and has been its Interim CEO and President since May 26, 2023. She had been a...


Board Members

NamePositionTenureCompensationOwnership
Suzanne Ildstad
Founder21.7yrsUS$1.33m11.88%
$ 65.7m
Mark McDade
Independent Director4.9yrsUS$130.42k0%
$ 0
Geoff MacKay
Independent Director4.9yrsUS$135.05k0%
$ 0
Sapna Srivastava
Independent Director2.8yrsUS$137.92k0%
$ 0
Francois Nader
Independent Chairman4.9yrsUS$175.92k0.90%
$ 5.0m
Sandip Agarwala
Independent Director4.9yrsUS$130.42k0%
$ 0
Karen Smith
Independent Director1.4yrsUS$249.58k0%
$ 0
Gaurav Shah
Independent Director2.8yrsUS$126.92k0%
$ 0

4.9yrs

Average Tenure

56yo

Average Age

Experienced Board: TALS's board of directors are considered experienced (4.9 years average tenure).